 | Up a level |
Agha, Mounzer E., Cohen, Adam D., Madduri, Deepu, Cohen, Yael C., Delforge, Michel, Hillengass, Jens, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan Mark, De Braganca, Kevin C., Varsos, Helen, Wang, Liwei, Vogel, Martin, Carrasco-Alfonso, Marlene, Akram, Muhammad, Wu, Xiaoling, Nesheiwat, Tonia and Einsele, Hermann (2021). CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta and Weisel, Katja . Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551